AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16971718
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy adherence
Trial: 10025903
Drug: VIM3ARAC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIM3ARAC regimen (teniposide, ifosfamide, mitoxantrone, mitoguazone, high-dose methotrexate, high-dose cytarabine, prednisolone)
Trial: 10025903
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival after treatment
Trial: 10025903
Drug: Relapse off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse off therapy and performance status <2 at relapse
Trial: 8749083
Drug: Lateral acceleration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral acceleration steps of 0.05 g, 0.1 g, 0.24 g of 600 ms duration
Trial: 2375136
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg QS liquid
Trial: 2375136
Drug: two 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 200 mg QS tablets
Trial: 2375136
Drug: 550 mg
RxNorm normalized name: xylitol 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 550 mg QP liquid
Trial: 2375136
Drug: two 275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 275 mg QP tablets
Trial: 28314093
Drug: Pharmacogenetic (PGx)‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic (PGx)‐guided treatment
Trial: 18937820
Drug: Mild laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild laser treatment
Trial: 23793205
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil of Cymbopogon citratus at 1.25 μL/mL concentration, applied three times a week as shampoo and twice a day as cream for 40 days.
Trial: 23793205
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole formulations, applied as control for 40 days.
Trial: 16902744
Drug: Heavyweight PP
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavyweight PP mesh (Prolene 10 x 15 cm, 1.5 g, group I, n = 232)
Trial: 16902744
Drug: Mixed PP-
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed PP- and Polyglactin mesh (Vypro II, 10 x 15 cm, 0.53 g, group II, n = 217)
Trial: 16902744
Drug: Light-weight titanized
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-weight titanized PP mesh (Ti-Mesh, 10 x 15 cm, 0.24 g, group III, n = 223)
Trial: 8677083
Drug: Control (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (weekly pelvic examinations only)
Trial: 28001016
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg) before breakfast for 90 days
Trial: 24714415
Drug: AST‐120 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST‐120 plus once‐monthly administration of continuous EPO receptor activator (CERA)
Trial: 20369705
Drug: Qianlie Jiedu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianlie Jiedu Capsule + Rufloxacin
Trial: 19080291
Drug: Failed early
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Failed early aspiration (volume of first daily aspirated secretions ≤ 20 ml)
Trial: 11826413
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (propranolol + isosorbide‐5‐mononitrate)
Trial: 10463324
Drug: Zolmitriptan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (5 mg orally)
Trial: 10463324
Drug: Ketanserin (5-HT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (5-HT receptor antagonist)
Trial: 7547098
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium 40 mg
Trial: 7022736
Drug: Atropine sulphate
RxNorm normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulphate (4 mg)
Trial: 7022736
Drug: Atropine methonitrate
RxNorm normalized name: Atropine methonitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine methonitrate (2 mg)
Trial: 7022736
Drug: Fenoterol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (400 μg)
Trial: 7022736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atropine methonitrate with fenoterol
Trial: 7022736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atropine sulphate with fenoterol
Trial: 29781725
Drug: Expanded cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expanded cognitive stimulation therapy (CST) model combined with tai chi, 14 sessions, twice a week
Trial: 29781725
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control group received treatment as usual initially and expanded CST model later
Trial: 23064538
Drug: HIV, HSV‐2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV, HSV‐2, and treponemal antibodies detected
Trial: 18575162
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of 0.1 mg morphine, 0.015 mg fentanyl and 15 mg hyperbaric bupivacaine (Group I, n = 20)
Trial: 18575162
Drug: Psoas compartment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II, n = 20)
Trial: 18575162
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of 0.1 mg morphine, 0.015 mg fentanyl and 15 mg hyperbaric bupivacaine (Group I)
Trial: 12616845
Drug: National registry
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: National registry for drug-induced QT prolongation
Trial: 10561636
Drug: 50‐g glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50‐g glucose beverage
Trial: 10561636
Drug: 28 jelly
RxNorm normalized name: Ophthalmic Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 jelly beans (50 g simple carbohydrate)
Trial: 8916999
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 mg, 12 h prior to surgery
Trial: 8916999
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 800 mg, 2 to 4 hours prior to surgery
Trial: 1863010
Drug: dipyridamole 75
RxNorm normalized name: dipyridamole 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dipyridamole 75 mg three times daily and aspirin 330 mg once daily
Trial: 1863010
Drug: physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physical exercise and dipyridamole 75 mg three times daily and aspirin 330 mg once daily
Trial: 17095617
Drug: New agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New agents for the treatment of acute leukemia
Trial: 15143375
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch therapy, education and motivation
Trial: 1299499
Drug: 40 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg.kg‐1 L‐ornithine.HCl
Trial: 1299499
Drug: 100 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg.kg‐1 L‐ornithine.HCl
Trial: 1299499
Drug: 170 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 170 mg.kg‐1 L‐ornithine.HCl
Trial: 6744203
Drug: Chemotherapy (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (6 cycles of Adriamycin (45 mg/m2), vincristine (1.2 mg/m2), and cyclophosphamide (200 mg/m2 for 5 days) every 4 weeks)
Trial: 6744203
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (radiotherapy and chemotherapy)
Trial: 6744203
Drug: Levamisole immunotherapy
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole immunotherapy (150 mg a day, 2 days weekly)
Trial: 1564302
Drug: Acute i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute i.v. administration of erythromycin (500 mg every 8 hours for 24 hours)
Trial: 1564302
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral therapy with erythromycin (500 mg three times daily for 15 weeks)
Trial: 22576305
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate ointment
Trial: 8964395
Drug: Budesonide 10
RxNorm normalized name: budesonide 100 MCG/ACTUAT Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 10 mg daily
Trial: 30682445
Drug: Sipuleucel-T after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sipuleucel-T after sensitizing radiation therapy (Arm B)
Trial: 26991468
Drug: Oral pentoxyfylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pentoxyfylline 400 mg thrice daily for 3 weeks
Trial: 26991468
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet thrice daily for 3 weeks
Trial: 22569029
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg kg(‐1) following remifentanil infusion at 0.5 μg kg(‐1) min(‐1)
Trial: 9407256
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplement (2.9 g.day-1) containing leucine, isoleucine, valine, glutamine, and carnitine
Trial: 9407256
Drug: Lactose (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (3 g.day-1)
Trial: 8171216
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg two times daily for 3 months
Trial: 3513752
Drug: Phenmetrazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenmetrazine (25 mg)
Trial: 3513752
Drug: Pemoline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline (75 mg)
Trial: 11491175
Drug: Prednisolone treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone treatment (5 days)
Trial: 11491175
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (5 days)
Trial: 30528698
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RPCRC and 4Kscore
Trial: 30528698
Drug: RPCRC-4Kscore combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPCRC-4Kscore combination
Trial: 27481512
Drug: G-CSF application
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF application (yes)
Trial: 27481512
Drug: G-CSF application
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF application (no)
Trial: 24736628
Drug: Lobeglitazone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 0.5 mg
Trial: 19846796
Drug: Intraperitoneal open-loop
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal open-loop insulin delivery (control)
Trial: 18035206
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg/d
Trial: 15707858
Drug: Formoterol 36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 36 microg TID via Aerolizer (total daily dose 108 microg)
Trial: 15707858
Drug: Salbutamol 600
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 600 microg TID via pMDI (total daily dose 1800 microg)
Trial: 29550525
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS treatment (1 mA, 3 sessions per week for 6 weeks)
Trial: 20015525
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg once a day added to pioglitazone 30 mg
Trial: 20015525
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice a day added to pioglitazone 15 mg
Trial: 8867263
Drug: Phentolamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine 0.5 mg/kg over 20 min
Trial: 8867263
Drug: Phentolamine 1
RxNorm normalized name: phentolamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine 1 mg/kg over 10 min
Trial: 6367617
Drug: Estradiol-17 beta
RxNorm normalized name: ESTRADIOL 17-BETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol-17 beta 4 mg daily
Trial: 6367617
Drug: Estradiol-17 beta
RxNorm normalized name: ESTRADIOL 17-BETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol-17 beta 2 mg daily
Trial: 26901812
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (0, 1.25, 2.5, 5, or 10 grams daily for 16 weeks)
Trial: 26901812
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel with anastrozole (suppressing conversion of androgens to estrogens)
Trial: 25281437
Drug: Colloid preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid preload (6% hydroxyethyl starch 130/0.4 500 mL before spinal anesthesia)
Trial: 25281437
Drug: Crystalloid co-load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid co-load (Ringer's acetate solution 1000 mL administered rapidly starting with intrathecal injection)
Trial: 22458343
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injections with local anesthetic
Trial: 22458343
Drug: Epidural injections
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injections with local anesthetic alone (Control)
Trial: 20147463
Drug: Fiber-enriched meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber-enriched meal (psyllium, 23.0 g)
Trial: 12126546
Drug: Epidural 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural 2% lidocaine 10 ml combined with 2.5 microg/ml of fentanyl 30 minutes before skin incision followed by 0.125% ropivacaine and 2 microg/ml fentanyl infusion at 9ml/h to the end of surgery (Group II)
Trial: 12126546
Drug: Epidural 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural 2% lidocaine 10 ml combined with 2.5 microg/ml of fentanyl and 0.15 mg/ml of droperidol 30 min before incision followed by 0.125% ropivacaine and 2 microg/ml fentanyl infusion at 9ml/h to the end of surgery (Group III)
Trial: 10410825
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of propranolol administered IC into the treated artery during balloon inflations
Trial: 10410825
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg IC propranolol
Trial: 25056567
Drug: Extended-release dexmethylphenidate
RxNorm normalized name: dexmethylphenidate Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release dexmethylphenidate (d-MPH)
Trial: 25056567
Drug: Extended-release mixed
RxNorm normalized name: Amphetamine Mixed Salts Extended-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release mixed amphetamine salts (MAS)
Trial: 19933235
Drug: Meloxicam 15
RxNorm normalized name: meloxicam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 15 mg/day for five consecutive days
Trial: 19933235
Drug: Meloxicam 30
RxNorm normalized name: meloxicam 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 30 mg/day for five consecutive days
Trial: 17681986
Drug: No preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preparation (Group 3)
Trial: 11999639
Drug: pimobendan (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pimobendan (1.25 or 2.5mg twice daily)
Trial: 1959
Drug: Mequitazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mequitazine (10 mg/24 hrs)
Trial: 7313613
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Diazepam and 200 ppm MeCl
Trial: 27516073
Drug: Stimulant dependence
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant dependence
Trial: 24457404
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg bid for 6 months
Trial: 24457404
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg qd for 6 months
Trial: 20880335
Drug: Weekly paclitaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly paclitaxel, 80 mg/m², for 12 cycles (B1) when sensitivity test positive
Trial: 20880335
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (A): Weekly paclitaxel without sensitivity test
Trial: 15555694
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy plus pharmacotherapy
Trial: 15555694
Drug: Multifamily psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifamily psychoeducational group therapy plus pharmacotherapy
Trial: 9894374
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 2.5 mg (increased to 5 mg or 10 mg if necessary)
Trial: 26255474
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (salmon calcitonin added to calcium and calcitriol)
Trial: 26255474
Drug: Comprehensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive group (incrementality waist musculi dorsi function exercise added to treatment group)
Trial: 23297680
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (Control)
Trial: 21872139
Drug: OMT (Optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT (Optimal Medical Treatment)
Trial: 19465671
Drug: Progestelle progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progestelle progesterone cream 20 mg
Trial: 19465671
Drug: Progestelle progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progestelle progesterone cream 60 mg, 40 mg, 5 mg
Trial: 10431474
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of flash liberation tablet
Trial: 10431474
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of freeze-dried reference tablet (lyoc)
Trial: 6553504
Drug: IV infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions of gamma‐radiation‐sterilized cells of Propionibacterium granulosum strain KP‐45
Trial: 6553504
Drug: Cytostatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytostatic drugs only (adriamycin, cyclophosphamide, and 5‐fluorouracil)
Trial: 26817506
Drug: Higher-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-protein diet (2.4 g · kg(‐1) · d(‐1))
Trial: 26817506
Drug: Lower-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-protein diet (1.2 g · kg(‐1) · d(‐1))
Trial: 24629431
Drug: afoxolaner chews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: afoxolaner chews administered at a dosage of at least 6.3mg/kg (1×)
Trial: 24629431
Drug: afoxolaner chews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: afoxolaner chews administered at a dosage of at least 18.9 mg/kg (3×)
Trial: 24629431
Drug: afoxolaner chews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: afoxolaner chews administered at a dosage of at least 31.5mg/kg (5×)
Trial: 10566718
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g i.v. 30 min preintervention
Trial: 7049585
Drug: Meptazinol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (400 mg)